| | A-/T-/N- (n) | A-/T-/N + (n) | A-/T + /N- (n) | A-/T + /N + (n) | A + /T-/N- (n) | A + /T-/N + (n) | A + /T + /N- (n) | A + /T + /N + (n) |
|---|
Whole cohort (n = 123) | 37 | 2 | 6 | 13 | 15 | 3 | 2 | 45 |
Controls (n = 38) | 26 | - | 5 | 5 | - | - | - | 2 |
MCI-MCI (n = 29) | 8 | 1 | 1 | 3 | 7 | 1 | - | 8 |
MCI-ADD (n = 28) | 2 | - | - | 3 | 3 | 1 | 2 | 17 |
ADD (n = 28) | 1 | 1 | - | 2 | 5 | 1 | - | 18 |
- Amyloid/Tau/Neurodegeneration (A/T/N) classification based on previously reported cut-off levels of CSF AD biomarkers Αβ42, p-tau and t-tau [40]; (A +) Αβ42 < 630 pg/mL [47], (T +) p-tau > 66 pg/mL and (N +) t-tau > 394 pg/mL [40]. MCI-MCI patients with amnestic mild cognitive impairment that did not fulfil the ADD diagnostic criteria after 2 years, MCI-ADD patients with amnestic mild cognitive impairment that progressed to fulfil the ADD diagnostic criteria after 2 years follow-up, ADD patients with Alzheimer’s disease with dementia at baseline
